I've addressed the issue of the cell surface complex in a post elsewhere here. Basically, it will be important to identify the CLTX ligand to add granularity to which other cancers this therapeutic will be most effective against and potentially patient stratification but, since MMP-2 is associated with the complex and is acting just fine as a proxy, it is not a pressing issue. Technically, this is neither difficult or expensive to solve, it just requires time for the experiments to be done. Not a biggie though.
Jennifer addressed the issue of the cerebral edema in her webinar. She pointed out it is a very common complication in glioblastoma and, as such, the clinician graded CAR-T treatment only as a "possible" cause which essentially means probably not but can't rule it out. I doubt the cause of the edema in this one patient can ever be unequivocally determined, what is important is to observe the frequency of edema going forward in the trial compared to what would be seen in SOC.
Would really like to see the SNO presos!
CHM Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)